Dyne Therapeutics, Inc. (NASDAQ:DYN) Receives $37.75 Average PT from Analysts

Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) have been assigned an average rating of “Buy” from the nine research firms that are presently covering the firm, MarketBeat.com reports. Eight research analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month target price among brokers that have covered the stock in the last year is $40.78.

DYN has been the subject of several analyst reports. Stifel Nicolaus boosted their target price on Dyne Therapeutics from $35.00 to $41.00 and gave the stock a “buy” rating in a research report on Wednesday, March 6th. Oppenheimer reissued an “outperform” rating and set a $47.00 price target on shares of Dyne Therapeutics in a research report on Monday, May 6th. HC Wainwright upped their price objective on shares of Dyne Therapeutics from $36.00 to $48.00 and gave the company a “buy” rating in a research report on Monday. Jefferies Financial Group lifted their target price on Dyne Therapeutics from $36.00 to $42.00 and gave the stock a “buy” rating in a report on Monday. Finally, Chardan Capital increased their price target on Dyne Therapeutics from $31.00 to $42.00 and gave the stock a “buy” rating in a report on Tuesday.

Insider Transactions at Dyne Therapeutics

In other news, SVP Richard William Scalzo sold 3,429 shares of the business’s stock in a transaction on Thursday, February 29th. The shares were sold at an average price of $27.50, for a total value of $94,297.50. Following the sale, the senior vice president now owns 124,228 shares of the company’s stock, valued at $3,416,270. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In other Dyne Therapeutics news, insider Wildon Farwell sold 1,585 shares of the firm’s stock in a transaction that occurred on Monday, March 11th. The stock was sold at an average price of $25.70, for a total value of $40,734.50. Following the completion of the transaction, the insider now directly owns 151,590 shares in the company, valued at $3,895,863. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, SVP Richard William Scalzo sold 3,429 shares of the business’s stock in a transaction that occurred on Thursday, February 29th. The stock was sold at an average price of $27.50, for a total value of $94,297.50. Following the transaction, the senior vice president now directly owns 124,228 shares in the company, valued at approximately $3,416,270. The disclosure for this sale can be found here. Insiders sold 934,841 shares of company stock valued at $23,103,069 over the last three months. Company insiders own 20.77% of the company’s stock.

Hedge Funds Weigh In On Dyne Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the company. Raymond James & Associates raised its stake in Dyne Therapeutics by 22.6% in the third quarter. Raymond James & Associates now owns 88,238 shares of the company’s stock valued at $791,000 after buying an additional 16,240 shares during the period. Bank of New York Mellon Corp lifted its stake in shares of Dyne Therapeutics by 4.8% during the 3rd quarter. Bank of New York Mellon Corp now owns 157,443 shares of the company’s stock worth $1,411,000 after buying an additional 7,196 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in Dyne Therapeutics by 58.5% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 8,379 shares of the company’s stock worth $75,000 after acquiring an additional 3,092 shares during the last quarter. TD Asset Management Inc bought a new stake in Dyne Therapeutics in the 3rd quarter valued at $206,000. Finally, Allspring Global Investments Holdings LLC grew its stake in shares of Dyne Therapeutics by 95.7% in the third quarter. Allspring Global Investments Holdings LLC now owns 9,310 shares of the company’s stock valued at $83,000 after acquiring an additional 4,552 shares in the last quarter. 96.68% of the stock is currently owned by institutional investors and hedge funds.

Dyne Therapeutics Trading Down 0.9 %

Shares of NASDAQ DYN opened at $31.25 on Friday. Dyne Therapeutics has a 1 year low of $6.40 and a 1 year high of $35.98. The firm’s 50-day moving average is $27.05 and its 200-day moving average is $20.50. The firm has a market capitalization of $2.73 billion, a PE ratio of -7.87 and a beta of 1.00.

Dyne Therapeutics (NASDAQ:DYN) last announced its quarterly earnings data on Thursday, May 2nd. The company reported ($0.81) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.81). As a group, equities research analysts anticipate that Dyne Therapeutics will post -3.1 earnings per share for the current fiscal year.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.